In a phase 2 trial in hepatorenal syndrome-acute kidney injury, stopped early, confirmed clinical improvement occurred in 48.6% with OCE-205 (n=37) vs 30.0% with placebo (n=10); not significant (p=0.48). Bradycardia occurred in 21.6% vs 0%.
RCTn = 47
Allegretti et al. OCE-205, a selective V1a receptor mixed agonist-antagonist, for the treatment of hepatorenal syndrome-acute kidney injury: A phase 2 randomized trial